1
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Letter to the editor about the article “Psychiatric disorders in post-acute COVID-syndrome 3 (PDPACS): Recommendations for health care professionals” (Falconi A et al., 2022)

      letter
      * ,
      European Neuropsychopharmacology
      Elsevier B.V. and ECNP.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dear editor, A recent letter published in your journal, “Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): Recommendations for health care professionals” from Falconi Paez et al. (2022), summarizes the characteristics of the psychiatric sequelae that many patients present after recovering from an acute SARS-CoV-2 infection, and provides a set of recommendations for the primary care providers regarding its early identification, follow-up appointments, and psychosocial management. First, we would like to express our agreement with the authors concerning the need of structured clinical guidelines to tackle the psychiatric disorders in Post-acute COVID-syndrome (PACS). Despite the apparent end of lockdowns and the decrease in COVID-19 hospitalization ratios, the mounting number of patients that are currently recovering from mild and moderate infections worldwide suggest that the demand for mental health attention will probably grow (Pavli et al., 2021). This will make even more urgent to have appropriate diagnostic and therapeutic tools. In this sense, we find it relevant to highlight some other aspects that can help optimize the assessment of this syndrome. In a previous article (Llach and Vieta, 2021), we described the constellation of mental symptoms organized around the “Mind Long COVID”. Although the incidence of post-acute COVID-19 dementia (1.6%) in people over 65 years is lower than mood (2%) or anxiety (4.7%) disorders, neurocognitive disturbances including not only brain fog but also difficulties with memory, concentration and executive function should be properly evaluated, as they are reported to impact patient's quality of life and daily functioning. Hence, cognitive impairment should also be ruled out during the first 6 months of follow-up. In addition, indications for referral to a mental health professional, either to a psychologist or a psychiatrist, should be stated in the guidelines. While it is important to not pathologize the majority, some of the patients may benefit from mental health services. Severity criteria may include, but not be limited to, the refractoriness of the symptoms beyond a basic psychosocial and pharmacological approach, the presence of structured suicidal ideation, or the presence of a baseline severe mental disorder. Finally, longitudinal studies are required to better define the protective factors and the biological underpinnings of Mind Long Covid. Mental health evaluations are necessary but are still unspecific and experts in the field have not yet agreed upon a stipulated timing or type of evaluations. The authors from the study propose a possibility regarding timing, but they don't explore potential evaluation objective methods. Still, considering the poly-syndromic nature of Mind Long Covid and PACS, it is maybe the time to elaborate useful transdiagnostic and rating tools. By reaching this consensus, future studies will have the possibility to respond yet unanswered questions and provide preventive strategies and treatments for Mind Long Covid. Declaration of Competing Interest CDLL has received CME-related honoraria, or consulting fees from Casen Recordati, with no financial or other relationship relevant to the subject of this article. GA has received CME-related honoraria, or consulting fees from Janssen-Cilag, Lundbeck and Angelini with no financial or other relationship relevant to the subject of this article.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals

          Post-COVID syndrome also known as long COVID refers to symptoms persisting for more than three weeks after the diagnosis of COVID-19. We reviewed the current evidence on post-COVID syndrome, focusing on its clinical manifestations and addressing the challenges for its management in primary healthcare. The incidence of post-COVID syndrome is estimated at 10–35%, while for hospitalized patients it may reach 85%. Fatigue is the most common symptom reported in 17.5–72% of post-COVID cases, followed by residual dyspnea with an incidence ranging from 10–40%. Mental problems, chest pain, and olfactory and gustatory dysfunction may affect up to 26%, 22% and 11% of patients, respectively. More than one third of patients with post-COVID syndrome have pre-existing comorbidities, hypertension and diabetes mellitus being the most common. Beyond the prolonged duration of symptoms, the scarce published data indicate that most patients with post-COVID syndrome have a good prognosis with no further complications or fatal outcomes reported. Given the clinical spectrum of patients with post-COVID syndrome, most of them will be managed by primary healthcare professionals, in conjunction with pre-existing or new co-morbidities, which, in turn, may increase the burden of COVID-19 on primary healthcare. In conclusion approximately 10% of patients with COVID-19 may have symptoms persisting beyond three weeks, fulfilling the criteria of post-COVID syndrome. Primary healthcare professionals have a key role in the management of patients with post-COVID syndrome. Research is needed to elucidate the pathogenesis, clinical spectrum, and prognosis of post-COVID syndrome.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Mind Long COVID: psychiatric sequelae of SARS-CoV-2 infection

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): Recommendations for health care professionals

              The number of patients recovering from the coronavirus disease 2019 (COVID-19) is increasing worldwide; however, they may still be at risk of suffering from Post-acute COVID-syndrome (PACS) with severe repercussions in their mental health. PACS is a complex sequel of systemic symptoms that persist in patients after four weeks of an acute COVID-19 infection (Nalbandian et al., 2021). PACS´s prevalence is 10 to 35% in the general population and up to 85% in previously hospitalized patients (Pavli et al., 2021). Psychiatric disorders in PACS (PDPACS) are multiple and include post-traumatic stress disorder (PTSD) (prevalence up to 20%), depression and anxiety (prevalence up to 23%), and insomnia (prevalence up to 26%) (Pavli et al., 2021). Health professionals providing primary care (primary care providers, PCPs) are the front line that identifies COVID-19 patients with a high risk of suffering from PDPACS and are responsible to give timely support. Nevertheless, there is still a need for guidelines and standardized procedures to achieve this task. This letter highlights the importance of the timely assessment of patients at risk of PDPACS, providing recommendations for health care professionals. The risk factors for severe acute COVID-19 are related to a higher risk of PDPACS (Pavli et al., 2021; Su et al., 2022). These risk factors include old age (>60), chronic diseases, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, increased levels of procalcitonin, D-Dimer, and IL-1, IL-6, and specific autoantibodies such as anti-SARS-CoV-2 nucleocapsid protein IgG (Nalbandian et al., 2021; Pavli et al., 2021; Su et al., 2022)(Fig. 1 ). Signs of PTSD, depression, anxiety, insomnia, brain fog, acute stress disorder, or adjustment disorder should be treated with prompt psychiatric support. Psychiatric screening and follow-up should be performed at four key moments: two weeks after clinical recovery (10 days since first symptoms) and then at the first, third, and sixth months after. Furthermore, if mental health issues or psychiatric symptoms appear at any time during or after COVID-19 recovery, a visit to PCPs should not be delayed (Fig. 1 ) Fig. 1 Recommendations regarding PDPACS based on pathophysiology and its recommended follow-up appointments. Fig 1 Early detection of psychiatric problems improves the patient's quality of life and reduces the risk of PDPACS. PCPs need to have training in providing accurate and evidence-based information about the course of illness and prognosis to the patients and their relatives, relieving the social and psychological stress (Gonçalves Júnior et al., 2020; Pavli et al., 2021). We recommend using the SPIKE protocol to deliver bad news and ease the conversations with patients mitigating their discomfort (Gonçalves Júnior et al., 2020). It is highly recommended that PCPs provide recommendations and guidance regarding the use of social media, as misinformation can cause population distress (Pavli et al., 2021; Polizzi et al., 2020). Encouraging social interaction and self-care (healthy eating habits, sleep hygiene, and regular exercise) may improve patient´s mental health (Pavli et al., 2021; Polizzi et al., 2020). However, these recommendations should be personalized according to patients' characteristics (Fig. 1 ). The proposed follow-up of COVID-19 patients, recovering or recovered, is essential and should be practiced by all health care professionals. Taking into account the recommendations mentioned in this letter may help decrease the burden of PDPACS in our society. Additionally, we hope that this letter will serve as a stepping stone for future clinical guidelines in the management of neuropsychiatric disorders in PACS. Funding Sistemas Médicos de la Universidad San Francisco de Quito, USFQ. Escuela de Medicina, Colegio de Ciencias de la Salud COCSA, USFQ, Quito, Ecuador. These funding sources had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. Author contributions AF, BN, CEV, YLT wrote the manuscript, reviewed and cured data; KZ and AC revised the manuscript basic science, JO, SF, GC revised manuscript clinical data and applications. GC provided the initial idea to target PDPCS and key information to analyze the subject. JO, SF and GC revised the neurological aspects of this article and provided feedback for a holistic approach. AC supervised, mentored and administered the work. AF, BN, CEV, YLT, KZ, JO, SF, GC and AC reviewed and commented on the manuscript to its final form and approval. AF, BN, CEV, YLT, AC conceptualization. Declaration of Competing Interest Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
                Bookmark

                Author and article information

                Journal
                Eur Neuropsychopharmacol
                Eur Neuropsychopharmacol
                European Neuropsychopharmacology
                Elsevier B.V. and ECNP.
                0924-977X
                1873-7862
                9 May 2022
                June 2022
                9 May 2022
                : 59
                : 56-57
                Affiliations
                [0001]Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, 170 Villarroel st, 12-0, 08036 Barcelona, Catalonia, Spain
                Author notes
                [* ]Corresponding author.
                Article
                S0924-977X(22)00174-2
                10.1016/j.euroneuro.2022.04.006
                9082953
                35550206
                e3f8cfb4-2a61-4567-8b88-2b230894a619
                © 2022 Elsevier B.V. and ECNP. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 26 March 2022
                : 8 April 2022
                Categories
                Correspondence

                Pharmacology & Pharmaceutical medicine
                Pharmacology & Pharmaceutical medicine

                Comments

                Comment on this article